Upexi (UPXI) Competitors $3.71 -0.08 (-2.11%) Closing price 04:00 PM EasternExtended Trading$3.76 +0.04 (+1.21%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends UPXI vs. PRPH, HCWB, FLGC, AIM, SNSE, IMNN, CRVO, TXMD, BMRA, and KPRXShould you be buying Upexi stock or one of its competitors? The main competitors of Upexi include ProPhase Labs (PRPH), HCW Biologics (HCWB), Flora Growth (FLGC), AIM ImmunoTech (AIM), Sensei Biotherapeutics (SNSE), Imunon (IMNN), CervoMed (CRVO), TherapeuticsMD (TXMD), Biomerica (BMRA), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry. Upexi vs. ProPhase Labs HCW Biologics Flora Growth AIM ImmunoTech Sensei Biotherapeutics Imunon CervoMed TherapeuticsMD Biomerica Kiora Pharmaceuticals ProPhase Labs (NASDAQ:PRPH) and Upexi (NASDAQ:UPXI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations. Which has better earnings and valuation, PRPH or UPXI? ProPhase Labs has higher revenue and earnings than Upexi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$44.38M0.23-$16.78M-$1.26-0.34Upexi$26M0.18-$23.66MN/AN/A Does the media prefer PRPH or UPXI? In the previous week, ProPhase Labs had 1 more articles in the media than Upexi. MarketBeat recorded 3 mentions for ProPhase Labs and 2 mentions for Upexi. ProPhase Labs' average media sentiment score of 0.29 beat Upexi's score of 0.19 indicating that ProPhase Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Upexi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in PRPH or UPXI? 9.5% of ProPhase Labs shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 20.7% of ProPhase Labs shares are held by insiders. Comparatively, 38.4% of Upexi shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in PRPH or UPXI? ProPhase Labs received 111 more outperform votes than Upexi when rated by MarketBeat users. Likewise, 49.78% of users gave ProPhase Labs an outperform vote while only 42.86% of users gave Upexi an outperform vote. CompanyUnderperformOutperformProPhase LabsOutperform Votes11449.78% Underperform Votes11550.22% UpexiOutperform Votes342.86% Underperform Votes457.14% Is PRPH or UPXI more profitable? Upexi has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. Upexi's return on equity of 0.00% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets ProPhase Labs-217.64% -62.92% -30.22% Upexi N/A N/A N/A Do analysts rate PRPH or UPXI? ProPhase Labs presently has a consensus target price of $11.00, indicating a potential upside of 2,489.45%. Upexi has a consensus target price of $25.00, indicating a potential upside of 573.85%. Given ProPhase Labs' stronger consensus rating and higher possible upside, equities research analysts clearly believe ProPhase Labs is more favorable than Upexi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Upexi 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, PRPH or UPXI? ProPhase Labs has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500. Comparatively, Upexi has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. SummaryProPhase Labs beats Upexi on 11 of the 16 factors compared between the two stocks. Get Upexi News Delivered to You Automatically Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPXI vs. The Competition Export to ExcelMetricUpexiMedicinals & botanicals IndustryBusiness SectorNASDAQ ExchangeMarket Cap$4.60M$1.16B$8.00B$9.14BDividend YieldN/AN/A2.21%3.98%P/E RatioN/A34.2928.8917.66Price / Sales0.185.55101.6881.09Price / CashN/A9.7631.2537.71Price / Book0.592.046.134.73Net Income-$23.66M-$53.10M$137.16M$225.42M7 Day Performance-11.67%1.19%-1.31%-0.44%1 Month Performance-1.85%0.09%-1.20%3.57%1 Year Performance-85.51%-10.78%20.64%19.20% Upexi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPXIUpexi2.9661 of 5 stars$3.71-2.1%$25.00+573.9%-84.7%$4.60M$26M0.00130PRPHProPhase Labs3.3416 of 5 stars$0.60-0.8%$11.00+1,747.8%-90.6%$14.21M$44.38M-0.47130Short Interest ↑Gap DownHCWBHCW Biologics2.0085 of 5 stars$0.37+3.2%N/A-76.9%$13.99M$2.84M-0.3740Short Interest ↓News CoveragePositive NewsGap DownFLGCFlora Growth2.6031 of 5 stars$0.96+3.2%$5.00+420.9%-37.9%$13.85M$76.07M0.00280Short Interest ↓News CoveragePositive NewsAIMAIM ImmunoTech1.6834 of 5 stars$0.21+8.4%$2.75+1,186.2%-52.6%$13.64M$200,000.00-0.4520SNSESensei Biotherapeutics4.4645 of 5 stars$0.53+4.2%$4.33+717.6%-40.2%$13.33MN/A-0.4540Short Interest ↑Gap DownIMNNImunon2.521 of 5 stars$0.91+1.7%$20.50+2,145.1%+58.0%$13.24M$500,000.00-0.4830Short Interest ↑News CoverageCRVOCervoMed3.555 of 5 stars$2.11flat$42.00+1,890.5%-73.9%$13.02M$7.14M0.004Short Interest ↓News CoverageTXMDTherapeuticsMD0.5282 of 5 stars$1.06+1.9%N/A-53.7%$12.22M$1.30M0.00420Short Interest ↓BMRABiomerica1.3792 of 5 stars$0.64-9.3%N/A-34.4%$11.74M$5.58M-1.7360Short Interest ↓Gap UpHigh Trading VolumeKPRXKiora Pharmaceuticals3.9467 of 5 stars$3.91+11.7%$10.00+155.8%-25.0%$11.73MN/A0.0010Positive News Related Companies and Tools Related Companies PRPH Alternatives HCWB Alternatives FLGC Alternatives AIM Alternatives SNSE Alternatives IMNN Alternatives CRVO Alternatives TXMD Alternatives BMRA Alternatives KPRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UPXI) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upexi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upexi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
